Kamis, 20 Agustus 2026

Thanks for signing up!

Header

Thank you for registering!

Important event details below

Jeff Brown here.

I always tell my readers that we have so much to look forward to.

That’s never been truer than today.

Years from now, when we look back on 2026, I believe we’ll remember it as one of the greatest moneymaking periods ever.

The economy… the stock market… your personal wealth…

They could all soar to unprecedented levels.

And it all begins with this historic, upcoming AI breakthrough.

AI researchers call it the “Holy Grail.” Going back to the 1950s, it’s always been the goal.

Along the way there have been critical advances, like ChatGPT.

But now, we’re about to see something much more powerful…

And it’s set to trigger an economic “big bang” unlike anything we’ve seen in our lifetimes – beginning in early 2026.

You’ll get all the during my event on Thursday, December 18, at 8 p.m. ET.

Here’s what to do right now

1) Check your inbox for my pre-event videos

They’ll break down:

  • Exactly what this AI breakthrough is

  • Why it’s so historic

  • The ways it could impact every part of your life, from life expectancy to cancer cures

  • How it could help you create generational wealth

  • And much, much more

2) Write down this link: americaunleashed2026.com

It’s where you’ll go to attend the main event on December 18, at 8 p.m. ET

3) Become an event VIP

This will allow you to receive text reminders before the event gets underway, and to claim a free special report: Jeff’s Massive 2026 Prediction.

I picked the #1 stock in the S&P in 2016, 2018, and 2019…

The #3 tech stock in 2020…

The #1 stock in the Nasdaq 100 in 2024 (three years in advance)…

And more.

Those who held on for the long term have seen gains as high as 2,340% and even 32,000%.

In this report, I’m revealing my forecast for 2026 – including how you can get ahead of it.

Claim Your Free Report

Sincerely,

Signature
Jeff Brown
Founder & CEO, Brownstone Research

© Brownstone Research
All Rights Reserved

1125 N Charles St
Baltimore, MD 21201

If you no longer wish to hear about this opportunity, you can unsubscribe here.

Anthropic IPO Set to Eclipse SpaceX Record?

Anthropic is preparing for an initial public offering that aims to match or surpass the record-setting $86.2 billion raised by SpaceX earlier this year. Backed by rapid adoption of its Claude models, the company is turning to Wall Street to fund the massive computing infrastructure required to lead the next generation of artificial intelligence.‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­‌   ­

Walmart Beat the Quarter. The Stock Didn't Care.

A $2.9B tariff refund did the heavy lifting. Now comes the hard part.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

This content is for informational purposes only and should not be considered financial advice. Investing involves risk.

The Cheap Investor is a publication of Investing Media Solutions, LLC.

To view our full policies: Disclaimer | Privacy Policy | Terms & Conditions

Update your email preferences or unsubscribe here

203 N La Salle Suite 2100
Chicago , Illinois 60601, United States

beehiiv logoPowered by beehiiv

I’m closing the list...

Get my August picks.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
 

Update your email preferences or unsubscribe here

5151 Pfeiffer Road, Suite 450
Cincinnati, Ohio 45242, United States

A Voucher Pathway, A Tight Float, And Why (NYSE American: NNVC) Is All Over Our Radar

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

A Voucher Pathway, A Tight Float, And Why (NYSE American: NNVC) Is All Over Our Radar


*Click Here To Get Our Alerts Faster Via SMS*


August 20th

Greetings Readers,


Most clinical programs follow a predictable order.


Approval first, shipping second.


NanoViricides, Inc. (NYSE American: NNVC) ran that sequence in reverse.


On August 10th, 2026, the company announced that ACOREP, the regulatory agency of the Democratic Republic of Congo, had cleared a Phase II clinical trial of NV-387 Oral Gum-mies as a treatment for Bund-i-bugyo E-bola-vi-rus and other E-bola strains.


Tucked into the same release was a detail most skimmed past: the drug product was already in the DRC.


The backdrop is severe. The company cited 4,141 confirmed cases and 1,889 confirmed deaths as of August 6th, 2026, then 4,945 confirmed cases and 2,325 deaths as of August 14th, with 101 new cases logged in a single 24-hour window and spread across six provinces. The crude fatality rate sits near 46%.


NV-387 does not work the way most antivirals do.


It is engineered to mimic heparan sulfate proteoglycan, a host cell surface feature the company states over 90% to 95% of human pathogenic vi-rus-es require in order to infect cells. The compound targets the doorway rather than the intruder, which is the basis for its broad-spectrum design.


Format matters as much as chemistry. NV-387 is delivered as an oral gummy that dissolves in the mouth without water. That contrasts with the two approved E-bola antibody drugs, both given by intravenous infusion and cleared only for the Zaire species. The company states there is no approved treatment for the Bund-i-bugyo variant driving this outbreak.


On August 18th, 2026, the company reported staff training underway, while Professor Patrick Katoto, Co-Director and Co-Founder of the Centre for Tropical Diseases and Global Health ("CTDGH"), and Associate Professor of Medicine, Epidemiology and Global Health at the Catholic University of Bukavu, Bukavu, DRC., was named to lead the trial, with first patient dosing expected within a few weeks absent outbreak delays. Om Sai Clinical Research Private Limited of India is the contract research organization.

A Fireside Chat And A Quiet Designation


Rewind seven weeks.


On June 29th, 2026, Dr. Anil R. Diwan, founder and president, sat for a recorded fireside chat.


He walked through how NV-387 is designed to work alongside vac.cines rather than compete with them, and how it departs from conventional antivirals.


The same week carried harder news.


The U.S. FDA granted Rare Pediatric Disease Drug designation for NV-387 as a treatment for measles, which opens the door to a Priority Review Voucher should the drug later w-i-n approval.


Diwan framed it in commercial terms, saying the designation and voucher “make a strong business case for development of NV-387 as a drug for the treatment of Measles.


The company noted a separate voucher changed hands for $195Mn earlier this year.


NV-387 had already received Orphan Drug designation for measles.

The Shift: Four Steps In Six Weeks


What followed was compressed. On July 8th, 2026, Noble Capital Markets initiated coverage with an Outperform rating and a $6.00 price target, authored by analyst Robert LeBoyer.


On July 24th, it priced a registered direct offering of approximately $3.8Mn covering 2,516,339 shares plus warrants exercisable at $1.75, with D. Boral Capital LLC as placement agent.


Four days later it confirmed financing was complete to support the anticipated E-bola trial.


Designation, coverage, capital, clearance.

About NanoViricides, Inc. (NYSE American: NNVC)


NanoViricides is a a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections.


It owns its multi-kilogram-scale cGMP-capable manufacturing facility outright with no mortgage, producing both drug substance and drug product in house.


Management states the plant can supply every program through human trials.


The underlying platform is licensed on an exclusive, worldwide basis from TheraCour Pharma, Inc., founded by Dr. Anil R. Diwan.


Rather than building around a single asset, the model applies one chemistry to many vi-rus-es.


NV-387 addresses E-bola, m-pox and sm-all-pox, measles, and a planned respiratory basket covering RSV, influenza and cor-ona-vi-rus-es.


NV-HHV-1 targets shingles.


Biological testing runs through academic, private and federal laboratories, which limits internal spending.


More Sources: NNVC Website.

We're Tracking 7 Key Potential Catalysts Backing (NYSE American: NNVC)


#1. Phase II Clearance Landed Inside An Active Out-break. Few clinical-stage developers get a green light while the target disease is still spreading, and NNVC now holds that clearance in DR Congo.


#2. Drug Product Reached The Country Before The Approval Did. Shipping and site logistics normally add months to an African trial start, and NNVC handled that step before clearance arrived.


#3. An Oral Gum-my Sidesteps Infusion Infrastructure Entirely. Competing E-bola treatments call for intravenous administration, while the format behind NNVC dissolves in the mouth without water.


#4. Public Float Sits Below 22Mn Shares. The reported float is approximately 21.08Mn shares, which makes NNVC a low float idea where the potential for heightened volatility may be significant.


#5. Two FDA Designations Open A Voucher Pathway In Measles. Orphan Drug and Rare Pediatric Disease Drug status put NNVC on a path where a voucher could be issued upon a future approval, and one such voucher sold for $195Mn this year.


#6. Published Coverage Carries A $6.00 Target Price. Noble Capital Markets reiterated in August with a continued Outperform rating, giving NNVC a documented third-party reference point.


#7. One Compound Feeds Four Separate Programs. E-bola, m-pox, measles and a planned respiratory basket all draw on the same molecule, so NNVC can generate several readouts from one chemistry.

Closing Thoughts


NanoViricides, Inc. (Nasdaq: NNVC) is not a finished story.


NV-387 remains experimental, Phase II has not dosed its first patient, and clearance to run a clinical trial is a different matter from drug approval.


What has changed is the setting.


A small Connecticut developer with its own plant and a float under 22Mn shares now has regulatory clearance, a trial lead, a contract research organization, and product already positioned inside what the company calls the largest recorded E-bola out-break, against a variant with no approved treatment.


Readers who track how narratives form before they are widely recognized may want to keep NNVC on the radar and review the company's releases directly.


We're initiating coverage on NanoViricides, Inc. (Nasdaq: NNVC).


Be on the lookout for updates coming out soon. Talk shortly.


Sincerely,

Kai Parker

StockWireNews


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)